---
title: "Sino Biopharm Showcases Promising Obesity Antibody Data and Expands Weight-Loss Pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286328735.md"
description: "Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing, presented promising preclinical data for TQF6422, a monoclonal antibody aimed at obesity treatment, at the European Congress on Obesity 2026. The drug demonstrated significant fat reduction and muscle preservation in animal models, outperforming competitors. With a favorable safety profile and plans for clinical trials, TQF6422 is part of a broader weight-loss pipeline, including other innovative therapies. Analysts rate Sino Biopharmaceutical (HK:1177) stock as a Buy, with a target price of HK$8.70, reflecting confidence in its growth in the obesity treatment market."
datetime: "2026-05-13T23:16:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286328735.md)
  - [en](https://longbridge.com/en/news/286328735.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286328735.md)
---

# Sino Biopharm Showcases Promising Obesity Antibody Data and Expands Weight-Loss Pipeline

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Sino Biopharmaceutical ( (HK:1177) ) has issued an update.

Sino Biopharmaceutical announced that subsidiary Chia Tai Tianqing has presented preclinical data for TQF6422, a fully human ActRII A/B monoclonal antibody, at the European Congress on Obesity 2026. The drug is designed to promote skeletal muscle growth while enhancing fat breakdown, aiming to deliver simultaneous fat loss and muscle gain.

In animal models, TQF6422 showed more than tenfold higher in vitro activity than comparable candidates, strong fat reduction and lean mass preservation at lower doses, and notable synergy when combined with semaglutide, including markedly greater fat loss and better maintenance of lean body mass. With a prolonged half-life, favorable safety profile, and a planned clinical trial application, TQF6422 positions the group in the emerging field of next-generation obesity therapies that prioritize “high-quality” weight loss, while its broader weight-loss pipeline, including an INHBE siRNA and an oral GLP-1RA approved for trials in China and the U.S., underscores its ambition to compete in the fast-growing global obesity treatment market.

The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

**More about Sino Biopharmaceutical**

Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group focused on innovative drug research and development, particularly in therapeutic areas such as metabolic diseases. Through subsidiaries including Chia Tai Tianqing Pharmaceutical Group, it is building a portfolio in the global weight-loss and diabetes markets, targeting long-acting and higher-quality treatment options for obese and overweight patients.

**Average Trading Volume:** 73,169,116

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$103.3B

See more insights into 1177 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)

## Related News & Research

- [Sino Biopharm Advances First-in-Class CCR8 Antibody Into Phase III Gastric Cancer Trial](https://longbridge.com/en/news/285458913.md)
- [GSK and SBP Group team up to advance bepirovirsen launch in China](https://longbridge.com/en/news/286073604.md)
- [Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate](https://longbridge.com/en/news/284532331.md)
- [Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus | OTLC Stock News](https://longbridge.com/en/news/286276734.md)
- [Alesis LLC Announces First Sleep Center Partnership for Alesis OSA1™ Treatment of the Root Cause of Most Sleep Apnea](https://longbridge.com/en/news/285977180.md)